The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Triggering global regulatory submissions this year for the treatment of obesity
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Subscribe To Our Newsletter & Stay Updated
